An interventional study of Coronary microvascular function assessment and Coronary microvascular function assessment in Coronary Artery Disease, Microcirculation Resistance and Microcirculation; Biomarkers; Myocardial Ischemia, sponsored by Medical University of Bialystok. Recruiting at 1 site in Poland. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-04-08.
Sponsored by Medical University of Bialystok · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 154 studies in Coronary Artery Disease with a site in Poland — 33 open to participants now, 47 under way, 4 of them phase 3. Coronary Artery Disease · Poland.
Among the 154 studies in Coronary Artery Disease with a site in Poland, this one is the 78th largest by planned enrollment of the 114 interventional ones that give a count, is one of 11 that started in 2025, is one of 64 with no phase, reaches primary completion later than 30 of the 46 other live ones, and was the 153rd registered.
4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.
Browse Coronary Artery Disease studies →33 of the 154 studies in Coronary Artery Disease with a site in Poland are open now. Recruiting first, the newest first:
Teleflex · Sites in Poland, United States, France and 1 more country
Ages 18–80
Shunmei Medical · Sites in Poland, France, Germany and 1 more country
Ages 18+
Dolnośląskie Centrum Chorób Serca im.prof. Zbigniewa Religi MEDINET Sp. z o.o. · Sites in Poland
Ages 18+
Collegium Medicum w Bydgoszczy · Sites in Poland
Ages 18+
Fondazione Ricerca e Innovazione Cardiovascolare ETS · Sites in Poland, Italy, Romania and 1 more country
Ages 18+
A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →
Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
154 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 9 · Phase 3 25 · Phase 4 18
First in 1999; this study’s year is marked. 11 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 180 is above the median of 123 across 3,011 interventional studies indexed under Coronary Artery Disease.
Median enrollment 348 across the 114 interventional studies, 585 across the 40 observational. Of the 91 that completed or were terminated, 23 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
75 of 154 have an industry lead sponsor. The 10 most frequent:
Medical University of Bialystok is the lead sponsor of 72 studies on the registry; 18 are open to participants now.
Medical University of Bialystok has 3 studies filed under Coronary Artery Disease — fewer than ten, so there is no comparison to draw.
9 of the studies in Coronary Artery Disease with a site in Poland that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03781492Silesian Centre for Heart DiseasesStable Angina Management and Treatment | 2026-12-31 |
| NCT04545112XeltisXeltis Coronary Artery Bypass Graft (XABG) First in Human (FIH) | 2027-02 |
| NCT07078370Vascudyne, Inc.Safety Study of Acellular Tissue Engineered Vessel for Coronary Artery Bypass | 2027-03-30 |
| NCT06451146Regional Cardiology Center, The Copper Health Centre (MCZ),Lower Silesian Orbital Atherectomy Registry (LOAR) | 2027-05-01 |
| NCT07091682Biotronik AGSafety and Clinical Performance of the Freesolve Resorbable Magnesium Scaffold System in the Treatment of Subjects With Long de Novo Lesions | 2027-06 |
Add all 9 to your calendar (.ics) → With an account.
Among the 154 studies in Coronary Artery Disease with a site in Poland, from their registry updates:
This tab as a report to print or save as PDF → With an account.
COMA.NET (Coronary Microcirculation Analysis Network) is a prospective, randomized, open-label, parallel-group clinical trial designed to determine whether endotype-guided pharmacotherapy is superior to standard care in improving quality of life in patients with ischemia with non-obstructive coronary arteries. Approximately 180-190 participants with objective ischemia will be randomized to either the control or the intervention group.
Pharmacotherapy based on the endotype established during intracoronary assessment will be introduced in the intervention arm of the study. The primary endpoint is the change in the Seattle Angina Questionnaire (SAQ) score from baseline to 3 months. Secondary endpoints include the diagnostic accuracy of transthoracic echocardiographic coronary flow velocity reserve (CFVR), the incidence of adverse events, associations between biomarkers and coronary microvascular dysfunction (CMD), and the identification of risk factors for specific CMD endotypes.
Participants will undergo invasive functional evaluation of the coronary microcirculation, measurement of echocardiographic CFVR, and analysis of selected circulating biomarkers. The study cohort will be followed up at three and six months and will include reassessment of quality of life (Seattle Angina Questionnaire, EuroQol 5-Dimensions 5-Level questionnaire, 12-item Short Form Health Survey), anxiety (Generalized Anxiety Disorder-7 score), and functional status (6-minute walk test).
The study began in October 2025. Primary completion is anticipated in October 2027, and the overall study completion date is expected in March 2028.
According to the European Society of Cardiology (ESC) guidelines on chronic coronary syndromes, up to 70% of patients presenting with anginal symptoms and ischemia on non-invasive tests demonstrate no significant coronary artery disease on coronary angiography (INOCA - ischemia with non-obstructive coronary arteries). The underlying pathophysiology of this condition may include functional or structural abnormalities of the coronary microcirculation.
The aforementioned ESC guidelines recommend invasive coronary functional testing as a primary diagnostic strategy in persistently symptomatic patients with ischemia with non-obstructive coronary arteries (INOCA) or angina with non-obstructive coronary arteries (ANOCA) and impaired quality of life, despite medical treatment (Class I recommendation). Identification of the specific coronary microvascular dysfunction (CMD) endotype or epicardial vasospastic angina is crucial for the introduction of optimal, targeted pharmacological therapy. Therefore, this study addresses a critical evidence gap. As a superiority trial, it aims to determine whether endotype-guided pharmacotherapy is superior to standard care in improving quality of life and relieving symptoms over a 3-month period. The primary hypothesis is that endotype-guided therapy will result in a greater improvement in the Seattle Angina Questionnaire (SAQ) score compared with standard therapy at 3 months of follow-up.
COMA.NET (Coronary Microcirculation Analysis Network) is a prospective, randomized, open-label, interventional clinical trial with a parallel-group design. The eligible sample for this study consists of adults with chronic coronary syndrome, proven myocardial ischemia, and excluded obstructive coronary disease, either by invasive coronary angiography or coronary computed tomography angiography (CCTA) (defined as no significant epicardial coronary stenosis).
The sample size was calculated using a conservative approach comparing mean change scores between groups, with a two-sided alpha level of 0.05 and 80% statistical power. Under these assumptions, approximately 160 evaluable participants are required. We anticipate an attrition rate of 15% (including loss to follow-up and incomplete questionnaire data); thus, the total planned enrollment is approximately 180-190 participants.
Participants will be randomized in a 1:1 allocation ratio to one of two arms: the intervention group or the control group. Randomization will be performed using a simple randomization procedure based on a computer-generated randomization sequence with permuted blocks of variable size (4 and 6).
According to the study protocol, prior to hospital admission, all participants will be adequately prepared by discontinuing pharmacotherapy known to interfere with vasoreactivity (e.g., non-dihydropyridine calcium channel blockers such as verapamil and diltiazem), in accordance with appropriate washout periods.
On admission, blood and urine samples will be collected for analysis of redox and inflammatory biomarkers, including non-enzymatic antioxidants, enzymatic antioxidants, total antioxidant capacity and oxidative status, markers of oxidative damage, cytokines, chemokines, growth factors, damage-associated molecular patterns (DAMPs), and matrix metalloproteinases (MMPs 1-14) and their tissue inhibitors. All biomarker analyses will be performed using validated laboratory methods according to established protocols.
Overall quality of life (QoL) assessment will be performed using the Seattle Angina Questionnaire (SAQ), EuroQol 5-Dimensions 5-Level questionnaire (EQ-5D-5L), Generalized Anxiety Disorder-7 (GAD-7) score, 12-item Short Form Health Survey (SF-12), and Six-Minute Walk Test (6MWT) distance at baseline and follow-up.
All participants will undergo transthoracic echocardiography. Coronary flow velocity in the left anterior descending (LAD) artery will be assessed using pulsed-wave Doppler at rest and during regadenoson-induced hyperemia. Coronary flow velocity reserve (CFVR) will be calculated as the ratio of hyperemic to resting coronary flow velocity.
Subsequently, invasive diagnostics will be performed in both groups in two consecutive stages:
Thereafter, following the examinations, patients will complete a numerical rating scale evaluating discomfort associated with the procedures.
In the intervention arm, antianginal treatment will be initiated in accordance with current ESC guidelines and tailored to specific CMD endotypes. The control group will receive standard pharmacotherapy according to current clinical practice, without endotype-specific treatment selection.
Participants initially assigned to the control group will cross over to the intervention arm at the 3-month follow-up. Following treatment revision according to the diagnosed endotype, both groups will be reassessed by telephone at 6 months from baseline using the previously described scales. Participants in the intervention arm will receive a follow-up telephone call one month after initiation of the intervention to assess clinical status, medication tolerance, adherence, and, if appropriate, to up-titrate prescribed medications.
At 3 months after the index hospitalization, participants in the intervention arm will undergo outpatient follow-up evaluation, including the SAQ, EQ-5D-5L, SF-12, 6-minute walk test, and GAD-7 score. Statistical analyses will be performed according to the intention-to-treat (ITT) and per-protocol principles.
The primary endpoint is the between-group difference in change in SAQ Summary Score at 3 months.
Secondary endpoints include:
This trial is designed to provide comprehensive data regarding the epidemiology, pathophysiological endotypes, and biomarkers of coronary vasomotor disorders in patients with INOCA. Furthermore, it will evaluate the clinical utility of invasive and non-invasive diagnostic tests and assess the impact of endotype-based pharmacotherapy on patient-related outcomes. The findings may contribute to the refinement of diagnostic algorithms and patient-centered management strategies.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
a. Chronic coronary syndrome c. Anginal symptoms > CCS class I or angina equivalent d. Myocardial ischemia confirmed by non-invasive testing e. Provision of to participate in the study
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants undergo invasive and non-invasive assessment of coronary microvascular function to determine the INOCA endotype. The invasive assessment includes intracoronary acetylcholine provocation testing followed by guidewire-based measurement of coronary flow reserve and index of microvascular resistance during pharmacologically induced hyperemia. Non-invasive assessment includes echocardiographic coronary flow velocity reserve measurement in the left anterior descending artery. Based on the identified endotype of coronary microvascular dysfunction, participants receive guideline-directed pharmacotherapy targeted to the underlying mechanism in accordance with contemporary European Society of Cardiology recommendations. Follow-up assessments include quality-of-life questionnaires, functional capacity testing, and laboratory evaluation.
Diagnostic Test: Coronary microvascular function assessment
Participants undergo the same invasive and non-invasive assessment of coronary microvascular function. Pharmacotherapy is determined by the treating physician according to standard clinical practice, without protocol-mandated endotype-guided treatment selection.
Diagnostic Test: Coronary microvascular function assessment
Comprehensive invasive and non-invasive evaluation of coronary microvascular function used to determine microvascular dysfunction endotype and guide treatment selection.
Also known as: Endotype-guided management
Comprehensive invasive and non-invasive evaluation of coronary microvascular function used to determine microvascular dysfunction endotype without endotype-guided management.
Also known as: Physician-guided standard care
Effectiveness of endotype-guided pharmacotherapy for coronary microvascular dysfunction
Comparison of the effectiveness of targeted pharmacotherapy tailored to the specific endotype of coronary microvascular dysfunction versus standard guideline-based pharmacotherapy. Assessment of changes in angina-related health status over time between study groups using the Seattle Angina Questionnaire (SAQ) ranging from 0 to 100, with higher scores indicating better health status and less angina-related limitations.
Time frame: Assessed at baseline and at 3 months follow-up
Prognostic value of selected blood and urinary biomarkers
Assessment whether selected biochemical markers measured in blood and urine are associated with the presence and severity of coronary microvascular dysfunction and whether they provide incremental prognostic information.
Time frame: 12 months
EuroQol 5-Dimension 5-Level questionnaire (EQ-5D-5L) index score
Assessment of changes in health-related quality of life including mobility, self-care, usual activities, pain/discomfort and anxiety/depression, ranging from -0.590 to 1.000 (based on values set for Polish population), with higher scores value indicating better health status, evaluated before and after targeted pharmacotherapy.
Time frame: Assessed at baseline, after 3 and 6 months
Diagnostic value of echocardiographic coronary velocity flow reserve (CFVR) assessment
Assessment of the diagnostic performance of echocardiographically measured coronary flow velocity reserve in detecting coronary microvascular dysfunction, compared with invasive coronary function testing as the reference standard.
Time frame: 12 months
12-item Short Form health survey (SF-12) score
Assessment of changes in health-related quality of life reflecting physical and mental health status, ranging from 0 to 100, with higher scores indicating better health status, evaluated before and after targeted pharmacotherapy.
Time frame: Assessed at baseline, after 3 and 6 months
Generalized Anxiety Disorder-7 (GAD-7) score
Assessment of changes in anxiety severity, ranging from 0 to 21, with higher scores indicating greater anxiety severity, evaluated before and after targeted pharmacotherapy.
Time frame: Assessed at baseline, after 3 and 6 months
Six-Minute Walk Test (6MWT) distance
Assessment of changes in functional exercise capacity over time before and after targeted pharmacotherapy.
Time frame: Assessed at baseline and after 3 months
Risk factors for specific endotypes of coronary microvascular dysfunction
To identify clinical, demographic, and biochemical factors associated with the occurrence of individual endotypes of coronary microvascular dysfunction.
Time frame: 12 months
Prevalence of coronary microvascular dysfunction endotypes in the Polish population
Determination of the frequency of individual endotypes of coronary microvascular dysfunction in the studied Polish population and to describe their clinical characteristics.
Time frame: 12 months
Adverse events
Assessment of the incidence and severity of adverse events occurring during the study period, including those related to diagnostic procedures and pharmacotherapy.
Time frame: 3 months
Plan to share: No
No publications or documents are linked to this record.
Started Oct 2025 (actual). Primary completion is estimated for Oct 2027, 24 months after the start.
Of 756 non-industry interventional studies with no phase under Coronary Artery Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 53. This study's planned 24 months is below that.
Counting every sponsor, half of 933 studies reached it within 30 months; a quarter within 15 and three quarters within 50.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Medical University of Bialystok